高压氧联合依达拉奉和奥扎格雷钠治疗进展性脑梗死的近期疗效观察  

Short-Term Effect of Hyperbaric Oxygen Combined with Edaravone and Ozagrel Sodium in Treating Progressive Cerebral Infarction

作　　者：陈伏萍[1] 于兴旭[1] 

机构地区：[1]辽宁医学院附属第一医院神经内科,锦州121000

出　　处：《中国循证医学杂志》2013年第4期413-416,共4页Chinese Journal of Evidence-based Medicine

摘　　要：目的观察高压氧联合依达拉奉和奥扎格雷钠治疗进展性脑梗死的近期疗效和安全性。方法将进展性脑梗死患者65例按入院先后分为试验组(高压氧联合依达拉奉和奥扎格雷钠,33例)和对照组(依达拉奉联合奥扎格雷钠,32例),治疗14天,并在治疗前、后分别评价神经功能缺损程度(NIHSS)、日常生活活动能力(ADL)和临床疗效。结果试验组患者NIHSS、ADL评分均较对照组有显著改善,两组差异均有统计学意义(P<0.05);试验组临床有效率达90.91%,明显高于对照组,两组差异有统计学意义(P=0.028)。两组均未见严重不良反应发生。结论高压氧联合依达拉奉和奥扎格雷钠治疗进展性脑梗死近期疗效显著,安全性好,具有一定的临床推广价值。Objective To observe the short-term effect and safety of hyperbaric oxygen combined with edaravone and ozagrel sodium in treating progressive cerebral infarction. Methods A total of 65 in-patients with acute progressive cerebral infarction were randomly divided into two groups： 33 in-patients in the trial group were treated by hyperbaric oxygen combined with edaravone and ozagrel sodium, while the other 32 in-patients in the control group were treated by edaravone and ozagrel sodium. The course of treatment was 14 days. The following indications were assessed before and after the treatment respectively： the national institutes of health stroke scale （NIHSS）, activities of daily living （ADL）, and clinical effects. Results This study showed that the scores of both ADL and NIHSS in the trial group were higher than those in the control group, with significant differences （P〈0.05）, The clinical effective rate of the trial group was 90.91% which was obviously higher than the control group with a significant difference （P=0.028）. There were no obvious adverse reactions in both groups. Conclusion Hyperbaric oxygen combined with both edaravone and ozagrel sodium is notable in short-term effect and safe, thus it is worth being popularized in clinical treatment.

关 键 词：进展性脑梗死 高压氧 依达拉奉 奥扎格雷钠 随机对照试验 

分 类 号：R743.3[医药卫生—神经病学与精神病学]